February 27, 2018 / 8:00 AM / in 8 months

BRIEF-DBV Technologies Announces Result From Phase II Study of Viaskin Milk

Feb 27 (Reuters) - DBV TECHNOLOGIES SA:

* ANNOUNCED ON MONDAY, RESULT FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

* POSITIVE PRELIMINARY RESULTS SUPPORT VIASKIN MILK’S POTENTIAL AS THE FIRST TREATMENT FOR PATIENTS SUFFERING FROM IGE-MEDIATED COW’S MILK PROTEIN ALLERGY (CMPA)

* A STATISTICALLY SIGNIFICANT DESENSITIZATION TO MILK WAS OBSERVED IN CHILDREN AGES TWO TO 11 TREATED WITH VIASKIN MILK 300 ΜG FOR 12 MONTHS

* COMPANY EVALUATING OPTIMAL DOSING/PATIENT POPULATION FOR FUTURE STUDIES

* ANNOUNCES EVALUATING THE EFFICACY AND SAFETY OF THREE DOSE REGIMENS OF VIASKIN MILK (150 ΜG, 300 ΜG, 500 ΜG) IN 198 PATIENTS FOR THE TREATMENT OF IGE-MEDIATED

Source text : bit.ly/2F4XeWZ

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below